Virbac Stock Drops 2.5% and Breaks Its Support at €329.50

A Decline that Accentuates Underperformance Below the Three Moving Averages

Virbac shares lose 2.48% at €315.00, in an SBF 120 that is up slightly (+0.15%). The stock is among the index's largest losers, with a decline of 4.55% over the week and 11.39% over three months. The price falls below the €329.50 support level, extending the bearish trend that began in the spring.

The technical configuration remains unfavorable: the price is below the MM20 at €344.98 (a gap of -8.69%) and even more so below the MM50 at €356.36 (a gap of -11.61%). The RSI at 41 indicates persistent selling pressure without reaching the oversold zone, leaving the stock exposed to further bearish tests. The break of the technical support monitored since mid-June, when the stock approached €332, marks a clear break from the stabilization phase observed in mid-June.

Jefferies Lowers Price Target to €361 and Maintains Hold

Jefferies has adjusted its view on the laboratory today, with a price target reduced from €368 to €361, while maintaining a hold rating. Based on the current price, the revised target offers a theoretical potential of about 14.6%, but the continuation of a neutral rating reflects a lack of directional conviction by the broker. Today's decline occurs in a tense market environment: the Fed's minutes released yesterday confirm a cautious stance on inflation, while the IMF has maintained its global growth forecast at 3.0% for 2026, with disinflation 'pausing'.

This backdrop weighs on the valuations of defensive growth stocks like animal health. The next technical anchor point for the stock is the €329.50 threshold, now breached downwards, with the €315 zone becoming the new level observed during the session.